Iodine‑125 brachytherapy for choroidal melanoma by using Ocuprosta seeds with indigenous non‑collimated plaques: Our initial experience.

Purpose: Brachytherapy is the gold‑standard treatment for choroidal melanoma. This study evaluated iodine‑125 brachytherapy by using Ocuprosta seeds with indigenous non‑collimated plaques in Asian patients. Methods: Retrospective single‑center study in a tertiary care hospital of 12 eyes with choroidal melanoma in 12 Asian patients who underwent brachytherapy with Ocuprosta seeds fixed on non‑collimated plaques and had a follow‑up of at least 32 months (mean: 42.4 ± 9.5 months; median: 40 months). Radiotherapy was planned after developing the digital 3D model of the tumor within the eye by using radiological images and clinical pictures. Ocuprosta iodine‑125 seeds were used on indigenous non‑collimated gold plaques to deliver the radiation for precalculated time. “Successful outcome” was taken as a decrease in the volume of the tumor, and “unsuccessful outcome” was defined as no change in the tumor volume or increase in the tumor volume at 24 months after brachytherapy. Results: The mean decrease in tumor volume was 21% (914.5 ± 912.2 mm³ to 495.7 ± 633.6 mm³ ) after brachytherapy, which correlated with the baseline volume of the tumor. Ten eyes (83.3%) showed a reduction in tumor volume, whereas two eyes showed an increase in the volume of the tumor after brachytherapy. One of the cases with a reduction in tumor size developed neovascular glaucoma. Enucleation was done in three eyes. A globe salvage rate of 75% and tumor regression rate of 83% were seen in the present study using Ocuprosta seeds. Conclusions: Iodine‑125 brachytherapy with uncollimated indigenous gold plaques is an effective treatment modality for choroidal melanomas in Asian patients. [ABSTRACT FROM AUTHOR]